Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cybin Inc. CYBN
$0.30
-$0 (-1.64%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
58033774.00000000
-
week52high
1.14
-
week52low
0.27
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.89673500
-
EPS
-0.21000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 февр 2022 г. в 21:00
Описание компании
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Roth Capital | Buy | 28 апр 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
The 7 Most Promising Psychedelic Stocks to Buy in February
InvestorPlace
05 февр 2023 г. в 14:30
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
Psychedelic Sunday: Competitive Strategies
Seeking Alpha
15 янв 2023 г. в 11:45
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
Scrutinizing Psychedelic Stocks
Seeking Alpha
08 янв 2023 г. в 11:30
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
Zacks Investment Research
06 дек 2022 г. в 21:49
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Cybin: A Leading Early-Stage Psychedelics Play
Seeking Alpha
23 ноя 2022 г. в 07:01
Cybin has the technologies, intellectual property, and funding it needs to advance its flagship pipeline project and continue being a leader in the psychedelics space. There are a pair of catalysts coming in the next few months, and both imply significant upsides.